Metabolites and Safety, the MIST and ICH-M3 GUIDANCE and their Impact on ADME
Gerhard Gross, Lundbeck Pharma, speaking at ADME & Predictive Toxicology Europe 2012
In Vitro, Ex Vivo and in Models to Develop New Therapies for Renal Diseases
Frederick W. K. Tam, Imperial College London, speaking at ADME & Predictive Toxicology Europe 2012
Biotransformation: Still a Bottleneck for in Vitro Kinetic and Dynamic Approaches
Sandra Coecke, European Centre for the Validation of Alternative Methods, speaking at ADME & Predictive Toxicology Europe
In Silico Toxicology: Where are We at and Where are We Going?
John C. Dearden, Liverpool John Moores University, speaking at ADME & Predictive Toxicology Europe 2012
When is a Genotoxin not a Genotoxin?
Richard Walmsley, University of Manchester, speaking at ADME & Predictive Toxicology Europe
miRNA Replacement Therapy in Cancer through Polyplex-Mediated miRNA Delivery In Vivo
Professor Achim Aigner, Institute of Pharmacology / bpc, Philipps-University Marburg, speaking at RNAi Europe 2011.
Biotests for Hazard Characterization of Waste
Dr Reinhilde Weltens, Vito, speaking at Advances in Biosensors and Biodetection.
Drug Discovery Outsourcing: the Importance of Integration in the Selection of Higher Quality Clinical Candidates
Simone Braggio, Director, Head of Drug Metabolism & Pharmacokinetics, Aptuit speaking at Pharma Outsourcing Congress 2011
Approach to Quick Lead Optimization Including Physicochemical and ADME Profiling
Pranas Japertas, Director, ACD Labs, Speaking at Medchem Europe 2011.